Who are VRVg-2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BCG-Bulgaria, RotaTeq, Rotavirus Vaccine, Live, Pentavalent, Varicella vaccine live, Norwalk Virus, Bacille Calmette Guerin (BCG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vrvg-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

VRVg-2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VRVg-2 (VRVg-2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Rotavirus structural proteins (VP4, VP7) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VRVg-2 (VRVg-2) — Sanofi Pasteur, a Sanofi Company. VRVg-2 is a recombinant rotavirus vaccine candidate designed to prevent rotavirus gastroenteritis through immunization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VRVg-2 TARGET	VRVg-2	Sanofi Pasteur, a Sanofi Company	phase 3	Live attenuated vaccine	Rotavirus structural proteins (VP4, VP7)
BCG-Bulgaria	BCG-Bulgaria	Bandim Health Project	marketed	Live attenuated vaccine
RotaTeq	RotaTeq	National Institute of Pediatrics, Mexico	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
Rotavirus Vaccine, Live, Pentavalent	Rotavirus Vaccine, Live, Pentavalent	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
Varicella vaccine live	Varicella vaccine live	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Norwalk Virus	Norwalk Virus	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Live attenuated vaccine
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VRVg-2 — Competitive Intelligence Brief. https://druglandscape.com/ci/vrvg-2. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing